Brokerages Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Target Price at $828.86

Key Points

• Regeneron Pharmaceuticals (NASDAQ:REGN) has received a consensus rating of "Moderate Buy" from 24 research firms, with 15 analysts recommending a buy and one suggesting a sell.
• The company recently reported $8.22 EPS for the quarter, missing analyst estimates, and its revenue was down 3.7% year-over-year.
• Institutional investors hold 83.31% of Regeneron's stock, with notable increases in investments from firms like Brighton Jones LLC, which raised its stake by 261.8%.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the twenty-four brokerages that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, six have issued a hold rating, fifteen have assigned a buy rating and two have given a strong buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $828.86.

A number of equities research analysts recently commented on the company. Guggenheim reaffirmed a "buy" rating on shares of Regeneron Pharmaceuticals in a research note on Friday. Wells Fargo & Company cut Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price objective for the company. in a research note on Friday. Robert W. Baird decreased their price objective on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a research note on Friday, April 25th. Cantor Fitzgerald assumed coverage on Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 price objective for the company. Finally, JPMorgan Chase & Co. decreased their price objective on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a research note on Monday, June 9th.

Regeneron Pharmaceuticals Price Performance

REGN stock traded up $13.41 during midday trading on Friday, reaching $558.87. 1,656,418 shares of the company's stock traded hands, compared to its average volume of 858,977. The company has a 50-day simple moving average of $538.64 and a two-hundred day simple moving average of $604.99. Regeneron Pharmaceuticals has a 1-year low of $476.49 and a 1-year high of $1,211.20. The company has a market cap of $60.34 billion, a price-to-earnings ratio of 14.23, a PEG ratio of 2.05 and a beta of 0.33. The company has a quick ratio of 4.03, a current ratio of 4.93 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). The firm had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The firm's quarterly revenue was down 3.7% on a year-over-year basis. During the same period last year, the business posted $9.55 earnings per share. On average, analysts anticipate that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were paid a $0.88 dividend. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.96%.

Institutional Trading of Regeneron Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Pinney & Scofield Inc. bought a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $25,000. E Fund Management Hong Kong Co. Ltd. raised its stake in Regeneron Pharmaceuticals by 344.4% in the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 31 shares during the period. Activest Wealth Management raised its stake in Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 21 shares during the period. Costello Asset Management INC bought a new stake in Regeneron Pharmaceuticals in the first quarter valued at approximately $27,000. Finally, Saudi Central Bank bought a new stake in Regeneron Pharmaceuticals in the first quarter valued at approximately $27,000. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.